Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Debt (2017 - 2025)

United Therapeutics' Total Debt history spans 14 years, with the latest figure at $200.0 million for Q1 2025.

  • For Q1 2025, Total Debt fell 66.67% year-over-year to $200.0 million; the TTM value through Mar 2025 reached $200.0 million, down 66.67%, while the annual FY2024 figure was $300.0 million, 57.14% down from the prior year.
  • Total Debt for Q1 2025 was $200.0 million at United Therapeutics, down from $300.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $800.0 million in Q1 2021 and bottomed at $200.0 million in Q1 2025.
  • The 5-year median for Total Debt is $800.0 million (2021), against an average of $676.5 million.
  • The largest annual shift saw Total Debt changed 0.0% in 2021 before it tumbled 66.67% in 2025.
  • A 5-year view of Total Debt shows it stood at $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then fell by 12.5% to $700.0 million in 2023, then plummeted by 57.14% to $300.0 million in 2024, then tumbled by 33.33% to $200.0 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Total Debt are $200.0 million (Q1 2025), $300.0 million (Q4 2024), and $400.0 million (Q3 2024).